Fig. 9

TPCA-1 chemosensitizes TNBC to paclitaxel and inhibits CXCL1^EV-dead-induced TNBC growth and lung metastasis in vivo. A Representative images of tumors and the tumor volume curves (n = 6). TPCA-1 (10 mg/kg/d) and paclitaxel (10 mg/kg/3d) were administered. B Representative images of the in vivo imaging assay and lung HE staining assay; n = 3. Scale bar: 100 μm. C, D The infiltration levels of CD45⁺/F4/80⁺/CD206⁺ TAMs and CD45⁺/F4/80⁺/PD-L1⁺ TAMs in the TME of mice following treatment with TPCA-1, paclitaxel, or the combination of TPCA-1 and paclitaxel; n = 3. E The CTC quantity in the peripheral blood of mice when they were treated as indicated; n = 3. F Representative images of tumors and the tumor volume curves (n = 6). EV-dead and EV-dead^rCXCL1 (200 μg/20 g weight, q3d) were administered by peritumoral injection. G Representative images of the in vivo imaging assay and lung HE staining assay; n = 3. Scale bar: 100 μm. H, I The infiltration levels of CD45⁺/F4/80⁺/CD206⁺ TAMs (n = 3) and CD45⁺/F4/80⁺/PD-L1⁺ TAMs (n = 6) in the TME of mice when they were treated as indicated. J The CTC quantity in the peripheral blood of mice when they were treated as indicated; n = 3. Data are presented as mean ± SD. ^*p < 0.05, ^**p < 0.01